Lenvatinib API Manufacturers

compare suppliers & get competitive offers

Filters

Reset

Selected filters:

Type
Production region
Qualifications
Country of origin

TOP RANKING

Located in:

India

Producer

Produced in:

India

Established in: 1984

MOQ: -

Employees: 21,650

Diverse portfolio of 180+APIs

1754+ DMF across global markets

1100+ patents filed, and more than 70 own patents granted

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • WC

  • GMP

  • CoA

  • FDA

  • MSDS

  • BSE/TSE

Contact supplier

Replies quickly

TOP RANKING

Located in:

India

Produced in:

India

Established in: 1989

MOQ: -

Employees: 5000+

6 production facilities approved by USFDA, AGES-Austria, PMDA, WHO

R&D Centers with capabilities of ANDAs, DMFs and NDDS

462+ patents filed for drug substances and polymorphs

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • WC

  • GMP

  • CoA

  • ISO9001

  • MSDS

  • BSE/TSE

Contact supplier

Replies quickly

HIGHLIGHTED

Located in:

China

Produced in:

China

Established in: 2013

MOQ: 1 kg

Employees: 25+

ISO9001 certified

Drug R&D center (in Hangzhou)

From lab scale (mg/g) to commercial scale (kgs/tons)

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • CoA

  • ISO9001

  • MSDS

  • CEP

  • WC

  • DMF

  • GMP

Contact supplier

Replies quickly

Produced in:

China

Established in: 2012

MOQ: 1 kg

Employees: 500+

GMP and ISO14001 certified manufacturing sites

Robust R&D team with 300+ professionals

Modern high-tech pharmaceutical enterprise

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • CoA

  • WC

  • MSDS

  • BSE/TSE

  • DMF

  • GMP

  • EDMF/ASMF

Contact supplier

Replies quickly

Producer

Produced in:

Turkey

Established in: 2022

MOQ: -

Employees: 100+

Operating on GMP guidelines with the most recent technologies and equipment

High-quality products at unrivaled prices

Specialize in Narcotic and Non-Narcotic APIs

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • WC

  • GMP

  • CoA

  • MSDS

Contact supplier

Replies quickly

Produced in:

China

Established in: 2019

MOQ: 1 kg

Employees: 10+

Focused on pharmaceutical industry

Reasonable price for the customers

Full service from R&D stage to commercial stage

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • GMP

  • CoA

  • MSDS

  • BSE/TSE

Contact supplier

Replies quickly

Produced in:

China

Established in: 2011

MOQ: 1 g

Employees: 10+

Fast Response and Good Communication

Willingness To Start From Small

Flexible Payment Terms

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • CoA

  • BSE/TSE

  • MSDS

  • ISO9001

Contact supplier

Replies in a day or 2

Distributor

Produced in:

World

Established in: 2005

MOQ: -

Employees: 200+

Portfolio of over 2,000 APIs

Precise quality control

End-to-end global regulatory support

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • CEP

  • GMP

  • CoA

  • MSDS

  • BSE/TSE

Contact supplier

Replies quickly

Located in:

China

Passed ISO9001:2015 and SGS audit

Provide one-stop CDMO service from R&D to production

Certifications: ISO9001: 2015, HALAL Certificate, Kosher Certification

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • CoA

  • ISO9001

  • MSDS

Contact supplier

Replies quickly

Located in:

United States
  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

Contact supplier

Replies quickly

Located in:

China
Contact supplier

Replies slower than most

Located in:

India

Producer

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • CoA

How does it work?

1
Register for free
icon

You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry

2
Start sourcing
icon

Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only

3
Send inquiries
icon

Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week

4
Get quotation
icon

Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news

5
Arrange agreement
icon

Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module

Looking for Lenvatinib API 417716-92-8?

Description:
Here you will find a list of producers, manufacturers and traders of Lenvatinib. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Lenvatinib 
Synonyms:
Lenvatinib Mesylate  
Cas Number:
417716-92-8 
DrugBank number:
DB09078 
Unique Ingredient Identifier:
EE083865G2

About Lenvatinib

Here you will find more information about Lenvatinib. Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, and 4;the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression.

In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers. Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib.

Ask the supplier for a certificate of analysis to find out more about the quality of Lenvatinib.

Lenvatinib is a type of Protein kinase inhibitors


Protein kinase inhibitors are a vital subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that play a crucial role in targeted cancer therapies. These inhibitors specifically target and block the activity of protein kinases, enzymes that regulate various cellular processes, including cell growth, division, and signal transduction.

Protein kinase inhibitors function by binding to the active site of protein kinases, preventing them from phosphorylating specific proteins and disrupting intracellular signaling pathways. This targeted approach inhibits the uncontrolled growth and proliferation of cancer cells, ultimately leading to their death.

The development of protein kinase inhibitors has revolutionized cancer treatment by providing more effective and less toxic alternatives to traditional chemotherapy. These drugs have demonstrated impressive results in the treatment of various cancers, including lung, breast, and leukemia.

The pharmaceutical industry invests heavily in research and development to discover novel protein kinase inhibitors with improved potency, selectivity, and pharmacokinetic properties. High-throughput screening, computational modeling, and structure-activity relationship studies are employed to identify potential lead compounds.

The success of protein kinase inhibitors in treating cancer has spurred significant interest in this subcategory of APIs. Ongoing research aims to expand their applications to other diseases, such as autoimmune disorders and neurological conditions.

In conclusion, protein kinase inhibitors are a valuable class of pharmaceutical APIs with immense potential for targeted cancer therapies. Continued advancements in this field hold promise for improved treatment outcomes and enhanced patient care.


Lenvatinib (Protein kinase inhibitors), classified under Anticancer drugs


Anticancer drugs belong to the pharmaceutical API (Active Pharmaceutical Ingredient) category designed specifically to combat cancer cells. These powerful medications play a crucial role in cancer treatment and are developed to target and destroy cancerous cells, preventing their growth and spread.

Anticancer drugs are classified based on their mode of action and can include various types such as chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, and hormonal therapy drugs. Chemotherapy drugs work by interfering with the cell division process, thereby inhibiting the growth of cancer cells. Targeted therapy drugs, on the other hand, are designed to attack specific molecules or genes involved in cancer growth, minimizing damage to healthy cells. Immunotherapy drugs stimulate the body's immune system to recognize and destroy cancer cells. Hormonal therapy drugs are used in cancers that are hormone-dependent, such as breast or prostate cancer, to block the hormones that fuel cancer cell growth.

These APIs are typically synthesized through complex chemical processes in state-of-the-art manufacturing facilities. Stringent quality control measures ensure the purity, potency, and safety of these drugs. Anticancer APIs undergo rigorous testing and adhere to stringent regulatory guidelines before being approved for clinical use.

Due to their critical role in cancer treatment, anticancer drugs are in high demand worldwide. Researchers and pharmaceutical companies continually strive to develop new and more effective APIs in this category to enhance treatment outcomes and minimize side effects. The ongoing advancements in the field of anticancer drug development offer hope for improved cancer therapies and better patient outcomes.



Lenvatinib manufacturers | traders | suppliers

We have 12 companies offering Lenvatinib produced in 5 different countries.

Get in contact with the supplier of your choice:

  • Dr. Reddy's from India, product country of origin India
  • Shilpa Medicare Ltd from India, product country of origin India
  • Senova Technology Co., Ltd. from China, product country of origin China
  • Shandong Loncom Pharmaceutical CO.,Ltd. from China, product country of origin China
  • PluviaEndo from Turkey, product country of origin Turkey
  • Apino Pharma Co., Ltd. from China, product country of origin China
  • Shandong Octagon Chemicals Limited from China, product country of origin China
  • LGM Pharma from United States, product country of origin World
  • Sinoway industrial Co.,Ltd from China, product country of origin China
  • R&S Chemicals from United States, product country of origin United States
  • Hunan Ouya Biological Co., Ltd. from China, product country of origin China
  • MSN Labs. from India, product country of origin India

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.